What happened with ARQT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Arcutis Biotherapeutics sells ZORYVE in the United States and Canada to treat plaque psoriasis, seborrheic dermatitis and atopic dermatitis. These medicines contain roflumilast and are applied to the skin. Product sales provide nearly all revenue, with ZORYVE foam and the plaque-psoriasis cream contributing most.
Sales depend on prescription demand and on private insurers and government health programs covering treatment and providing adequate reimbursement. A small group of major customers accounts for much of gross product sales. Arcutis also receives license fees and milestone payments from Huadong for rights in Greater China and Southeast Asia and Sato Pharmaceutical for rights in Japan, but these are a much smaller revenue source.
The business relies on rights licensed from AstraZeneca, to which Arcutis owes royalties on covered product sales, and on single-source outside manufacturers for ZORYVE supplies. Arcutis may promote its medicines only for uses consistent with their approved labeling; additional uses require regulatory approval before promotion.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Arcutis's results hinge on ZORYVE prescription growth and payer coverage in inflammatory skin diseases, where Galderma and LEO Pharma are important competitors missing from this list.
Pfizer competes for atopic dermatitis patients with Arcutis's ZORYVE creams through its topical Eucrisa and oral Cibinqo. Eucrisa also blocks PDE4, making it a particularly relevant rival among medicines applied to the skin.
Bausch Health competes directly with Arcutis for plaque psoriasis patients by selling topical treatments including Duobrii and Bryhali, alternatives to ZORYVE psoriasis products.
Novartis competes with Arcutis over plaque psoriasis treatment choices by selling Cosentyx, although Cosentyx treats the disease systemically rather than through a topical medicine like ZORYVE.
Oruka Therapeutics, Inc. could eventually compete for psoriasis patients using Arcutis's ZORYVE, though its antibodies act systemically and serve different treatment settings from topical medicines. It has no approved products or revenue yet; development progress on its psoriasis candidates ORKA-001 and ORKA-002 is the news to watch.
Aclaris Therapeutics, Inc. is developing immune-inflammatory treatments, including topical lepzacitinib, that could compete with Arcutis's ZORYVE atopic dermatitis creams. For lepzacitinib, watch its search for a partner to develop and commercialize the drug outside Greater China.
Arcutis relies on AstraZeneca's license for exclusive worldwide rights to use roflumilast in topical skin-disease treatments such as ZORYVE, paying AstraZeneca sales royalties and milestone payments. ZORYVE growth therefore brings license costs too: Arcutis paid a $10 million milestone when worldwide net sales reached $250 million in May 2025.
Arcutis Biotherapeutics, Inc. earningsThis company
Arcutis Biotherapeutics' report will show whether ZORYVE sales growth across formulations can outweigh supply, royalty and reimbursement pressures.
Read product sales by formulation alongside cost of sales, which includes manufacturing, distribution, royalties and amortization. Growth in both creams and foam without costs rising faster would show demand is broadening and more sales are reaching gross profit; growth concentrated in one formulation, or costs outpacing sales, would leave the breadth and margin contribution unproven.
Bausch Health Companies Inc earningsBHC
Bausch Health's report will show how demand for topical psoriasis treatments such as Duobrii and Bryhali is holding up against Arcutis Biotherapeutics' ZORYVE.
Look for disclosed sales or demand signals for Bausch Health's topical psoriasis treatments, including Duobrii and Bryhali. Steady or stronger demand would show these alternatives still attract patients, leaving Arcutis Biotherapeutics' ZORYVE to compete for prescriptions and coverage; weaker demand would soften that competitive signal, but would not establish that patients switched to ZORYVE.
Fed Interest Rate Decision
The Fed’s rate decision signals the direction of borrowing costs, which can change the interest Arcutis pays on its variable-rate loan and leave less or more cash for its business.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is higher than expected, broader borrowing costs may rise; because Arcutis’s loan rate is variable, its interest expense and debt-service costs may increase, leaving less cash for ZORYVE sales and development.
If it comes in below expectations
If the policy rate is lower than expected, broader borrowing costs may ease; Arcutis’s variable loan rate and interest expense may fall, leaving more cash for ZORYVE sales and development.
